Covid vaccines are not responsible for heart attacks: Min
Speaking at the inauguration of a heart health check-up camp for journalists, organised by Karnataka Working Journalists Association's district unit in Kalaburagi and Sri Jayadeva Cardiovascular Science and Research Hospital at Press Club, Jagat Circle, on Wednesday, he stated that ICMR and various institutions' studies found no connection between Covid vaccines and heart attacks. The govt has now classified heart attack deaths as a notifiable disease for public health agencies.
Postmortems will be conducted the following day for heart attack fatalities to determine the precise cause of death.
Due to increased heart attack cases in Hassan, an expert committee has been established. A free cardiology camp offering ECG, 2D echo and TMT check-ups has been organised at Jayadeva Hospital, Kalaburagi, considering journalists' health who serve society round the clock. He encouraged journalists to utilise these services.
Kalaburagi has seen several healthcare improvement initiatives, including a 200-bed Mother-Child Hospital, Indira Gandhi Children's Hospital, Nimhans Branch, and Institute of Diabetology. Plans are underway to establish a Minto Hospital branch in Kalaburagi for eye care services.
For maintaining good health, Patil advised following a balanced diet with nutritious food. He recommended avoiding tobacco, alcohol, and western-style foods like pizza, burgers, and fried items. He emphasised the importance of regular exercise, yoga, and meditation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
15 minutes ago
- Time of India
Rajnath visits KGMU to check on BJP functionary's health
Lucknow: Defence minister and Lucknow MP Rajnath Singh visited KGMU on Saturday to check on the health of senior BJP functionary Vindhyavasini Kumar. Kumar recently tested positive for Covid-19, but has since tested negative. The 77-year-old leader was admitted to the KGMU Trauma Centre last Saturday and was later shifted to the Medical Intensive Care Unit (MICU) in Gandhi Ward. Doctors informed Singh that Kumar's condition is improving and has been taken off the ventilator. They said his kidney infection is also gradually subsiding. During his visit, Singh met Kumar's family members at the vice-chancellor's office, including his daughter Jayati Srivastava, son-in-law Anoop Sharma, and sons Devesh Kumar and Vishwesh Kumar. He assured the family of all possible support and instructed the doctors to ensure the best treatment. Later, he also visited the residence of corporator Nagendra Singh to offer his condolences on the recent demise of his mother. Deputy chief minister Brajesh Pathak, former deputy CM and Rajya Sabha MP Dinesh Sharma, and mayor Sushma Kharkwal were also present. |
Time of India
an hour ago
- Time of India
City reports four more Covid cases
Mumbai: Maharashtra on Saturday reported four Covid-19 cases, all of which were detected in Mumbai, a health department official said. The state's tally since Jan 1 this year stands at 2,624, while that of Mumbai during this period is 1,043. While 41 people have died of the ailment, including 40 with comorbidities, the recovery count is 2,536. PTI
The Hindu
5 hours ago
- The Hindu
Enrolment in third phase clinical trials for India's first dengue vaccine nearly complete, says ICMR
Following an announcement by the Indian Council of Medical Research (ICMR) and Panacea Biotec Limited to initiate third phase trials, about 8,000 of the targeted 10,000 participants have enrolled in the third phase of clinical trials for a dengue vaccine in India, Manoj Murhekar, Director, National Institute of Epidemiology, ICMR, Chennai, told The Hindu. The trial will be rolled out at 20 centres across the country, Dr. Murhekar said. 'In India, all four serotypes of the dengue virus are known to circulate or co-circulate in many regions, so it's vital to ensure that we have an effective vaccine that achieves good efficacy for all four serotypes,'' he added. The trial is primarily funded by ICMR, with partial support from Panacea Biotec. Participants will be followed up for two years under projects spread across various centres, including Chennai, Pune, Hyderabad, and Delhi. There is currently no antiviral treatment or licensed vaccine for dengue in India. 'This landmark trial will evaluate the efficacy of India's indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec. The first participant in this trial was vaccinated last year at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak,'' a release issued by the Union Health Ministry said. The tetravalent dengue vaccine strain (TV003/TV005) originally developed by the National Institutes of Health, the U.S., has shown promising results in preclinical and clinical trials worldwide. Panacea Biotec, one of three Indian companies to receive the strain, is at the most advanced stage of developing a vaccine. The company has worked extensively on these strains to develop a full-fledged vaccine formulation and holds a process patent for this work. The first and second phases of the clinical trials of Indian vaccine formulations were completed in 2018-19, yielding promising results. Dengue is a major public health concern in India, which ranks among the top 30 countries with the highest incidence of the disease. The global incidence of dengue has been steadily increasing over the past two decades, with more than 129 countries reporting dengue viral disease by the end of 2023, according to the World Health Organization (WHO). In India, approximately 75-80% of infections are asymptomatic, yet these individuals can still transmit the infection through the bite of Aedes mosquitoes. Among the 20-25% of cases where symptoms are clinically apparent, children are at a significantly higher risk of hospitalisation and mortality. In adults, the disease can escalate into severe conditions, including the dengue hemorrhagic fever and dengue shock syndrome. The dengue virus has four serotypes, 1-4, with low cross-protection against each other, which means individuals can experience repeated infections.
